Novartis AG (NVS) Financial Statements
Historical financial data — 5 statements covering FY2021–FY2025
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an esta...
Novartis AG's revenue increased 9.6% year over year, from $51.72B to $56.67B.
Net income increased 17.1% over the same period, from $11.94B to $13.98B.
Over the 4-year period from FY2021 to FY2025, revenue grew by 29% in total.
Total debt increased by 12.9% to $35.46B.
The debt-to-equity ratio stands at 0.76, indicating a moderate leverage profile.
Novartis AG maintains a strong net profit margin of 24.7%.
Recent Financial Statements
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2021 | $43.97B | $24.02B | $32.24B | $10.06B | N/A | $131.79B | $31.09B | $67.82B |
| FY2022 | $43.46B-1.2% | $6.96B | $31.88B | $7.95B | N/A | $117.45B | $27.96B | $59.42B |
| FY2023 | $46.66B+7.4% | $14.85B | $34.19B | $9.77B | N/A | $99.94B | $26.44B | $46.75B |
| FY2024 | $51.72B+10.8% | $11.94B | $38.90B | $14.54B | N/A | $102.25B | $31.40B | $44.13B |
| FY2025 | $56.67B+9.6% | $13.98B | $42.98B | $17.64B | N/A | $110.95B | $35.46B | $46.55B |
Balance Sheet Summary (Latest Period)
Total Assets
$110.95B
Total Liabilities
$64.40B
Total Equity
$46.55B
Cash & Equivalents
$11.59B
Total Debt
$35.46B
Current Assets
$30.46B
Current Liabilities
$27.28B
Retained Earnings
$45.41B